• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Chemo-Immunotherapy Side Effects in Patients with Breast Cancer Referred to Outpatient Clinics in Tehran, Iran.

作者信息

Mesgartehrani Majid, Mesgartehrani Zeinab, Bakhtiari Zahra, Shakouri Mohammad, Saadat Alireza, Ghanei Mostafa, Norozian Dariush, Mesgartehrani Mohammad, Shabany Maryam

机构信息

Social Health Research Center, Nasim Institute, Tehran, Iran.

Department of Hematology and Oncology, Valiasr Hospital, Tehran, Iran.

出版信息

Iran J Public Health. 2022 Aug;51(8):1909-1911. doi: 10.18502/ijph.v51i8.10282.

DOI:10.18502/ijph.v51i8.10282
PMID:36249103
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9546815/
Abstract
摘要

相似文献

1
Chemo-Immunotherapy Side Effects in Patients with Breast Cancer Referred to Outpatient Clinics in Tehran, Iran.伊朗德黑兰门诊乳腺癌患者的化疗免疫治疗副作用
Iran J Public Health. 2022 Aug;51(8):1909-1911. doi: 10.18502/ijph.v51i8.10282.
2
Predictors of mammography screening among Iranian women attending outpatient clinics in Tehran, Iran.伊朗德黑兰门诊就诊的伊朗女性乳腺钼靶筛查的预测因素
Asian Pac J Cancer Prev. 2012;13(3):969-74. doi: 10.7314/apjcp.2012.13.3.969.
3
Gastrointestinal tumor board: an evolving experience in Tehran Cancer Institute.胃肠肿瘤多学科会诊：德黑兰癌症研究所的发展历程
Acta Med Iran. 2013 May 7;51(4):270-3.
4
Socio-demographic correlates of participation in mammography: a survey among women aged between 35- 69 in Tehran, Iran.参与乳房X光检查的社会人口统计学相关因素：伊朗德黑兰35至69岁女性的一项调查
Asian Pac J Cancer Prev. 2012;13(6):2717-20. doi: 10.7314/apjcp.2012.13.6.2717.
5
A retrospective institutional study of histopathologic pattern of Oral Squamous Cell Carcinoma (OSCC) in Tehran, Iran during 2006-2015.一项对2006年至2015年期间伊朗德黑兰口腔鳞状细胞癌（OSCC）组织病理学模式的机构回顾性研究。
J Res Med Sci. 2019 Jun 25;24:53. doi: 10.4103/jrms.JRMS_882_18. eCollection 2019.
6
Dietary patterns, nutrition, and risk of breast cancer: a case-control study in the west of Iran.饮食模式、营养与乳腺癌风险：伊朗西部的一项病例对照研究。
Epidemiol Health. 2019;41:e2019003. doi: 10.4178/epih.e2019003. Epub 2019 Jan 24.
7
Direct Costs of Asthma in a Referral Public Children's Hospital in Tehran, Iran.伊朗德黑兰一家转诊型公立儿童医院哮喘的直接成本
Iran J Allergy Asthma Immunol. 2018 Dec 3;17(6):601-603.
8
Time trends in the occurrence of major GI cancers in Iran.伊朗主要胃肠道癌症发病率的时间趋势。
Asian Pac J Cancer Prev. 2005 Apr-Jun;6(2):130-4.
9
Burden of breast cancer in Iran: a study of the Tehran population based cancer registry.伊朗乳腺癌负担：基于德黑兰人群癌症登记处的一项研究。
Asian Pac J Cancer Prev. 2006 Oct-Dec;7(4):571-4.
10
Decreasing trend of tumor size and downstaging in breast cancer in Iran: results of a 15-year study.伊朗乳腺癌肿瘤大小和降期的下降趋势：一项 15 年研究的结果。
Eur J Cancer Prev. 2010 Mar;19(2):126-30. doi: 10.1097/CEJ.0b013e328333d0b3.

本文引用的文献

1
[Progress of researches on and fascioliasis in Yunnan Province].[云南省片形吸虫病的研究进展]
Zhongguo Xue Xi Chong Bing Fang Zhi Za Zhi. 2020 Jul 15;33(3):317-319. doi: 10.16250/j.32.1374.2020077.
2
Cancer incidence in Iran in 2014: Results of the Iranian National Population-based Cancer Registry.2014 年伊朗癌症发病率：伊朗全国人群癌症登记处的结果。
Cancer Epidemiol. 2019 Aug;61:50-58. doi: 10.1016/j.canep.2019.05.009. Epub 2019 May 25.
3
Self-evaluation of Adjuvant Chemotherapy-Related Adverse Effects by Patients With Breast Cancer.患者对乳腺癌辅助化疗相关不良反应的自我评估。
JAMA Oncol. 2016 Apr;2(4):445-52. doi: 10.1001/jamaoncol.2015.4720.
4
Eribulin mesylate, a novel microtubule inhibitor in the treatment of breast cancer.甲磺酸艾日布林，一种治疗乳腺癌的新型微管抑制剂。
Cancer Treat Rev. 2012 Apr;38(2):143-51. doi: 10.1016/j.ctrv.2011.03.006. Epub 2011 May 8.
5
Frequency and cost of chemotherapy-related serious adverse effects in a population sample of women with breast cancer.乳腺癌女性人群样本中化疗相关严重不良反应的发生率及费用
J Natl Cancer Inst. 2006 Aug 16;98(16):1108-17. doi: 10.1093/jnci/djj305.
6
Continued use of trastuzumab (herceptin) after progression on prior trastuzumab therapy in HER-2-positive metastatic breast cancer.HER-2阳性转移性乳腺癌患者在先前曲妥珠单抗治疗进展后继续使用曲妥珠单抗（赫赛汀）。
Cancer Invest. 2006 Mar;24(2):187-91. doi: 10.1080/07357900500524629.